Navigation Links
Clinical Phase Ia Trial on MIV-711 Complete and Phase Ib Trial Commences
Date:8/21/2012

STOCKHOLM, Sweden, August 21, 2012 /PRNewswire/ --

Medivir AB (OMX: MVIR), the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, is reporting today that a clinical phase Ib trial of the company's candidate drug (CD) MIV-711 has commenced.

MIV-711 is a cathepsin K inhibitor intended to treat skeletal disorders that feature high bone resorption such as osteoporosis, rheumatoid arthritis and bone metastases. Cathepsin K is an enzyme that is important to the metabolism of bone and cartilage and, accordingly, inhibition of cathepsin K is expected to have a positive effect on these diseases.

MIV-711's clinical phase I program was initiated in May. Phase Ia was recently completed, in which increasing single doses were administered to healthy volunteers to evaluate safety, tolerability, pharmacokinetics and efficacy on biomarkers. The results were very promising and a phase Ib trial has now commenced in which repeated single daily doses will be administered to groups of healthy volunteers including post-menopausal women. Safety, tolerability, pharmacokinetics and efficacy on biomarkers will be evaluated during 7-14 days' treatment.

Charlotte Edenius, Medivir's EVP of Research and Development, commented: "the first part of the phase I program offered us important information to enable us to take the next step in the clinical development of MIV-711. The results also support our previous assessment that it will be possible to administer MIV-711 in a low single daily dose. We expect to be able to compile the complete phase I trial results by the end of this year."

About Medivir

Medivir is an emerging research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfo
'/>"/>

SOURCE Medivir
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Positive Clinical Study Results for BSPs HyperQ Technology
3. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
6. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
7. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
8. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
9. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 CORD:USE Cord Blood Bank – ... it has entered into an Equity and Exclusive Services ... licensed a series of patented technologies for the isolation of ... applications.  Tianhe is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... solutions for drug discovery and related life ... consortium has chosen Genedata Selector as its ... (NGS) data. FUNGITECT is a European consortium ... fungal diseases via individualized anti-fungal drug therapies. ...
(Date:9/30/2014)... , Sept. 30, 2014  KemPharm, Inc., ... discovery and development of proprietary new molecular entity ... Patent and Trademark Office (USPTO) issued U.S. Patent ... entitled, "Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl ... Making and Use Thereof." The patent, ...
(Date:9/30/2014)... , Sept. 30, 2014 FemCap Inc., ... health announces its receipt of a patent No: US, ... cup has also received FDA clearance in the U.S., ... the CE in Europe. This patent is related to its ... this issuance, the company is releasing FemmyCycle Teen, a ...
Breaking Biology Technology:CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2The FemmyCycle 2
... 16, Shire plc (LSE: SHP, NASDAQ: SHPGY ... U.S. District Court of the Southern District of,New York ... Shire,s patents: U.S. Patent No. 5,968,976 (",976 Patent"); U.S. ... , The lawsuit was filed ...
... and megabase capacity for the next generation sequencing ... febit today announced the official launch ... several biomedical studies of early access customers over ... and deep sequencing coverage for a broad range ...
... tester machine for medical pouches & sachets from Ireland-based manufacturer Sepha. ... ... A leak tester machine for pharmaceutical and medical pouches ... makes its U.S. market debut through U.S. distributor Service Industries ...
Cached Biology Technology:Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents 2Automated Sequence Capture for Next-Generation Sequencing Paves the Way for Personalized Medicine 2Automated Sequence Capture for Next-Generation Sequencing Paves the Way for Personalized Medicine 3U.S. Distributor Debut for PAKSCAN - a Pouch & Sachet Leak Tester Machine from Ireland-based Sepha Ltd. 2U.S. Distributor Debut for PAKSCAN - a Pouch & Sachet Leak Tester Machine from Ireland-based Sepha Ltd. 3
(Date:9/30/2014)... tetrachloroethylene (PCE) in drinking water may increase the ... a new study led by a Boston University ... published in the journal Environmental Health , ... among 1,766 women in Cape Cod, Ma., where ... the early 1980s by the installation of vinyl-lined ...
(Date:9/30/2014)... on Earth, but when the climate changes and temperatures ... The amount of time needed to adjust to new ... in the future, reveals a new study from researchers ... journal Proceedings of the Royal Society B . ... of greenhouse gases in the atmosphere. The greenhouse effect ...
(Date:9/30/2014)... in urban and farm runoff in Hawaii is causing ... , The study, published Tuesday in the peer-reviewed ... the runoff ends up in algae that the turtles ... eyes, flippers and internal organs. , Scientists at Duke ... and Atmospheric Administration (NOAA) conducted the study to better ...
Breaking Biology News(10 mins):Contaminated water linked to pregnancy complications, BU study finds 2Shape up quickly -- applies to fish, too! 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3
... University] The cactus, stalwart of the desert, has quite ... found the world over. In a paper published in ... Academy of Sciences , Brown University biologists and colleagues have ... and 10 million years ago and coincided with species explosions ...
... asses are descendants of the original ancestors of the horse ... now in danger of extinction, largely as a direct result ... Walzer,s group has been working together with colleagues in Germany, ... currently restricted to areas in Mongolia, China, India, Iran and ...
... ... cattle in native pasturelands in Brazil,s Pantanal and Cerrado regions can benefit ... Conservation Society. , The technique, which has been adapted ... small areas for shorter periods of time before moving onto other pastures. ...
Cached Biology News:Succulent plants waited for cool, dry Earth to make their mark 2Succulent plants waited for cool, dry Earth to make their mark 3A boring life -- the Asiatic wild ass in the Mongolian Gobi 2Grazing as a conservation tool 2
The F40 pump maintenance kit is used to service one F40 pump of a BioLogic DuoFlow workstation. It includes 2 piston seals, 4 check valves, seal removal tool, and 2 O-rings....
...
...
...
Biology Products: